Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:BNTCNYSE:IBIONASDAQ:ONCS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.13$0.15$0.11▼$1.25$5.93M-0.244.44 million shs282,814 shsBNTCBenitec Biopharma$6.86+2.1%$4.99$1.86▼$9.01$17.77M1.0367,576 shs26,465 shsIBIOiBio$1.91+7.3%$0.00$1.02▼$26.20$6.65M-3.533.11 million shs154,274 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+3.00%+1.82%-11.38%-4.29%-86.25%BNTCBenitec Biopharma+2.08%+43.51%+38.59%+140.70%+93.63%IBIOiBio+6.70%-2.05%+51.59%+190,999,900.00%+190,999,900.00%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-70.97%Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABNTCBenitec Biopharma1.57 of 5 stars3.53.00.00.02.30.80.0IBIOiBioN/AN/AN/AN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/ABNTCBenitec Biopharma3.00Buy$16.00133.24% UpsideIBIOiBioN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest IBIO, ONCS, BNTC, and ATXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.002/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.001/24/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ABNTCBenitec Biopharma$80K222.09N/AN/A$0.12 per share57.17IBIOiBio$2.38M2.79N/AN/A$15.15 per share0.13ONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)BNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)IBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/AONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest IBIO, ONCS, BNTC, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/A2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/A2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55BNTCBenitec Biopharma0.013.623.62IBIOiBio0.040.910.91ONCSOncoSec MedicalN/A0.890.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%BNTCBenitec Biopharma52.19%IBIOiBio7.90%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%BNTCBenitec Biopharma4.30%IBIOiBio1.12%ONCSOncoSec Medical1.32%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataIBIOiBio263.48 million3.45 millionN/AONCSOncoSec Medical404.55 million4.49 millionNot OptionableIBIO, ONCS, BNTC, and ATXI HeadlinesSourceHeadlineIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?aaii.com - June 29 at 2:37 AMONCS - OncoSec Medical Incorporatedfinance.yahoo.com - June 24 at 8:41 AM0 analysts rank ONCS stock as an Overweightknoxdaily.com - June 23 at 6:54 PMWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?markets.businessinsider.com - June 23 at 8:53 AMWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - June 15 at 2:49 PMWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?msn.com - June 15 at 9:48 AMOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 18 at 8:59 PMOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockmsn.com - May 16 at 4:15 PMOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 4:15 PMOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programfinance.yahoo.com - May 16 at 9:56 AMOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Programfinance.yahoo.com - April 27 at 8:26 AMOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 11 at 5:48 PMWhy OncoSec Medical Shares Are Soaring Todaymsn.com - April 10 at 4:15 PMOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 10 at 4:15 PMOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Tradingbenzinga.com - April 6 at 7:57 PMOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Studyfinance.yahoo.com - April 3 at 3:57 PMOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialmsn.com - April 3 at 10:57 AMOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatmentfinance.yahoo.com - April 3 at 10:57 AMOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%marketwatch.com - March 1 at 8:56 AMWhy is OncoSec Medical (ONCS) Stock Up 91% Today?msn.com - March 1 at 8:56 AMONCS.OQ - | Stock Price & Latest News | Reutersreuters.com - January 16 at 7:08 PMOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summarybenzinga.com - January 5 at 3:51 PMPeering Into OncoSec Medical's Recent Short Interestmsn.com - December 8 at 5:34 PMOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022finance.yahoo.com - December 5 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.iBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.